NewTimeSpace News: Fosun Pharma announced on July 24 that its controlling subsidiary Fosun Wanbang received approval from the National Medical Products Administration (NMPA). The DM1001 preparation is authorized for clinical trials targeting signs and symptoms of idiopathic Parkinson's disease in adults, with Phase I clinical trials planned to be carried out in China once conditions permit.
NewTimeSpace News: Haina Intelligent Equipment International Holdings Limited (01645.HK) announced that it has entered into a strategic cooperation agreement with Jinjiang Yuanshu Intelligent Technology and the Shenzhen Institute of Artificial Intelligence and Robotics to jointly set up a joint laboratory for intelligent production line robots with a three-year cooperation term. The joint laboratory will focus on R&D and commercialisation of technological areas including intelligent upgrading of production lines, industrial applications of embodied intelligence, visual inspection and digital twin.
NewTimeSpace News: On 24 July 2026, BIDU-SW(09888.HK) saw sluggish trading in the afternoon session. As of 14:38, the stock was quoted at HK$104.10, down 2.53%. Apollo Go has obtained an autonomous driving test license issued by the Transport Department of Hong Kong, with official road tests set to kick off on 27 July.
NewTimeSpace (newtimespace.com) reported that on July 24, 2026, the chip theme bucked the broader market trend and strengthened, with SMIC (00981.HK) fluctuating higher. As of 13:18, the stock was quoted at HKD 72.500, up 2.47%.
NewTimeSpace (newtimespace.com) reported that on July 24, 2026, the robotics theme weakened, with UBTECH (09880.HK) fluctuating lower. As of 13:04, the stock was quoted at HKD 78.050, down 4.99%.
NewTimeSpace News: Apollo Future Mobility (0860.HK) announced on July 23 that it delivered the first Apollo EVO production custom edition "Caribbean Dragon" in June 2026, which was officially unveiled at the Goodwood Festival of Speed 2026 in July 2026 as one of a limited edition of ten custom models. The Apollo EVO is powered by a 6.3-litre V12 naturally aspirated engine with a dry weight of approximately 1,300 kg, featuring a full carbon fibre monocoque body shell and carbon fibre crash structure, with a base price of approximately EUR 3,000,000 per unit.
NewTimeSpace News: Grand Pharmaceutical (00512.HK) announced on July 23 that its TCM Class 1.1 innovative drug GPN01360 for depression (liver depression and spleen deficiency syndrome) has completed the first patient enrollment and dosing in its Phase III clinical study in China. The randomized, double-blind, placebo-controlled, multi-center Phase III study plans to enroll 480 patients with 8 weeks of oral administration, with the primary endpoint being the change from baseline in HAMD-17 total score at Week 8. The product is based on the classical formula "Xiaoyao San" and is supported by the national "Major New Drug Innovation" program.
On 23 July 2026, Hong Kong-listed AI sector saw sharp divergence. AI chip and semiconductor chains suffered a deep pullback (HUA HONG GRACE and ILUVATAR COREX slumped more than 7%), while large language model concept stocks rallied collectively (MEITUAN-W rose 4.36% and BIDU-SW gained 2.3%). Autonomous driving stocks traded mixed.On the industrial front, seven central ministries issued requirements stipulating that newly-built intelligent computing centres must source no less than 75% of chips from domestic suppliers starting September. HORIZON ROBOT-W launched a USD450 million convertible bond issue and expects to turn profitable. UBTECH ROBOTICS leads the project to set a national standard for humanoid robot data. AMD entered a USD5 billion strategic partnership with Anthropic.The market is rapidly pricing in policies for computing power localisation. Capital is rotating from hardware players to application-focused firms, with pronounced structural rotation across the sector.
NewTimeSpace News: SBP Group (01177.HK) announced that Class 1 innovative drug IM-101 Injection (PreS1 recombinant fusion protein), developed by its subsidiary Chia Tai Tianqing, has secured clinical trial approval from NMPA for the treatment of chronic hepatitis B (CHB). IM-101 has the potential to break immune tolerance and rebuild HBV-specific immune responses. There are approximately 290 million chronic HBV carriers worldwide, including around 75 million cases in China.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that four pharmaceutical products of the Group have secured manufacturing approvals issued by NMPA. Classified as Category 4 chemical drugs, all are deemed to have passed generic consistency evaluation. The portfolio comprises Sodium Citrate Hemofiltration Replacement Fluid (5000ml), Benidipine Hydrochloride Tablets (4mg), 1.4% Polyvinyl Alcohol Eye Drops (0.4ml:5.6mg), and Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml & 1026ml). The approvals further enrich the Group’s product portfolio covering blood purification, hypertension, ophthalmology and parenteral nutrition.
NewTimeSpace News: On July 23, 2026, RoboSense (02498.HK) edged down moderately in afternoon trading. As of 15:10, its intraday quotation stood at HK$22.70, a drop of 1.22%. During the World Artificial Intelligence Conference (WAIC) held in Shanghai, RoboSense unveiled successive strategic cooperation partnerships with four corporations.
NewTimeSpace (newtimespace.com) reported that on July 23, 2026, the chip theme retreated during trading, with HUA HONG GRACE (01347.HK) fluctuating lower. As of 13:30, the stock was quoted at HKD 152.200, down 5.76%.
NewTimeSpace (newtimespace.com) reported that on July 23, 2026, the robotics theme showed choppy trading, with Midea Group (00300.HK) rising in volatile trading. As of 13:14, the stock was quoted at HKD 95.600, up 0.74%.
NewTimeSpace News: Keymed Biosciences Inc. (02162.HK) announced that its key pipeline asset CM512, a TSLP/IL-13 bispecific antibody, has been included in the Breakthrough Therapy Programme by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). CM512 is the world’s first IgG-like long-acting TSLP × IL-13 dual blocker.
NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that preclinical data of ASC36_35 FDC, a once-monthly injectable fixed-dose co-formulation of ASC36 and ASC35, has been accepted for short oral discussion at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). Data show the candidate delivers superior weight-loss effects compared with eloralintide combined with tirzepatide in diet-induced obese (DIO) animal models.
NewTimeSpace News: ORBUSNEICH (06929.HK) announced that the first patient has been enrolled in OM-0031, the pivotal clinical trial of its coronary paclitaxel drug-coated balloon (DCB) in Japan. The trial evaluates the safety and efficacy of the Group’s self-developed DCB product. It will be conducted across 25 leading cardiovascular centres nationwide in Japan, with full enrolment targeted by the end of 2027.
